Company

ProJenX, Inc.

ProJenX develops brain-penetrant therapies for ALS and other neurodegenerative diseases.

About

ProJenX is developing Prosetin, a MAP4K inhibitor therapy, and other brain-penetrant treatments for ALS and neurodegenerative diseases. Founded in 2021 by Arie Zask, Emily Lowry, Hynek Wichterle and Brent Stockwell, the company is based in New York, US. In November 2023, it raised USD 15 million in Series A funding led by Medical Excellence Capital.

2Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in